About this product
Overview
Neutobiv 5mg Tablet contains the active ingredient nebivolol, which belongs to the class of medications known as beta-blockers. It is primarily prescribed for the management of hypertension (high blood pressure) and certain cardiovascular conditions.
Active Ingredient
- Nebivolol: Nebivolol is a selective beta-1 adrenergic receptor antagonist with vasodilatory properties. It works by blocking the effects of adrenaline (epinephrine) on the heart and blood vessels, leading to decreased heart rate and relaxation of blood vessels, thereby reducing blood pressure.
Uses
Neutobiv 5mg Tablet is used for the following purposes:
- Hypertension: It is indicated for the treatment of hypertension to lower blood pressure and reduce the risk of cardiovascular events such as heart attacks and strokes.
- Heart Failure: Nebivolol may be prescribed as adjunctive therapy in the management of chronic heart failure to improve symptoms and reduce hospitalizations.
Mechanism of Action
Nebivolol exerts its pharmacological effects by selectively blocking beta-1 adrenergic receptors in the heart, leading to a decrease in heart rate and cardiac output. Additionally, nebivolol stimulates the release of nitric oxide (NO) from endothelial cells, resulting in vasodilation and improved blood flow.
Administration
Neutobiv 5mg Tablet is typically taken orally, with or without food, as directed by a healthcare professional. The dosage regimen may vary based on individual response and medical condition. It is important to take the medication regularly as prescribed to achieve optimal blood pressure control.
Side Effects
Common side effects of nebivolol may include:
- Fatigue
- Dizziness
- Headache
- Nausea
- Bradycardia (slow heart rate)
- Hypotension (low blood pressure)
- Peripheral edema (swelling of the extremities)
Precautions
- Use nebivolol with caution in patients with a history of bronchospastic diseases such as asthma or chronic obstructive pulmonary disease (COPD), as it may exacerbate respiratory symptoms.
- Abrupt discontinuation of nebivolol therapy should be avoided, as it may lead to rebound hypertension or worsening of heart failure symptoms.
- Patients should be monitored regularly for changes in blood pressure, heart rate, and signs of heart failure during treatment with nebivolol.
Contraindications
- Neutobiv 5mg Tablet is contraindicated in patients with severe bradycardia, heart block greater than first degree, cardiogenic shock, or decompensated heart failure.
- It should not be used in individuals with a known hypersensitivity to nebivolol or other beta-blockers.
This information is for general awareness only. It does not replace advice from your doctor or pharmacist. Always read the leaflet and follow the directions you were given.
Substitutes for Neutobiv 5mg Tablet
These medicines contain the same salt as Neutobiv 5mg Tablet (Nebivolol 5mg), so they are common substitutes. Compare their prices, and change brands only after checking with your doctor or pharmacist.
| Medicine | Manufacturer | Pack | Price |
|---|---|---|---|
| Nabiz 5mg Tablet | CCL Pharmaceuticals PTV AL Qamar | 14 tablets | Rs 210 |
| Danlol 5mg Tablet | Daneen Pharma | 14 tablets | Rs 211.20 |
| Betanorm 5mg tablet | Werrick Pharmaceuticals | 10 tablets | Rs 218 |
| Gneb 5mg Tablet | Genix Pharma | 14s | Rs 224 |
| Nabiloc 5mg Tablets | Nabiqasim Industries | 14 Tablets In a Pack | Rs 245 |
| Nebicare 5mg Tablet | Barrett Hodgson | 14s | Rs 250 |
| Nebtec 5mg Tablet | Pharmatec | 14 tablets | Rs 255.20 |
| Nebifix 5mg Tablet | Cell Laboratories | 14 tablets | Rs 260 |
Other strengths of Nebivolol
| Medicine | Manufacturer | Strength | Price |
|---|---|---|---|
| Nobu 2.5mg Tablet | Scotman Pharmaceuticals | 2.5mg | Rs 86 |
| Gneb 2.5mg Tablet | Genix Pharma | 2.5mg | Rs 96.04 |
| Nebtec 2.5mg Tablet | Pharmatec | 2.5mg | Rs 104.32 |
| Anvol 2.5mg Tablet | Obs-pharma | 2.5mg | Rs 118.07 |
See all brands and prices on our Nebivolol page.
Customer reviews
You must be logged in to post a review.




Reviews
Clear filtersThere are no reviews yet.